Bibliography
- KARIN M, BEN-NERIAH Y: Phosphorylation meets ubiquitination: the control of NE-KB activity. Ann. Rev. Immunol (2000) 18:621–663.
- ••Major review by the leading authority inthis area.
- BURKE JR: Targeting IKB kinase for the treatment of inflammatory and other disorders. Curr. Opin. Drug Discov. Dev. (2003) 6(5):720–728.
- ••Recent review of the medicinal chemistryof the area.
- BHAGWAT SS, BRYDON L, BENNETT YS et al.: The small molecule IKK2 inhibitor SPC-839 is efficacious in an animal model of arthritis. ACR Annual Scientific Meeting. San Francisco, USA (2001). Arthritis & Rheumatism.
- BURKE JR, PATTOLI MA, GREGOR KR et al.: BMS-345541 is a highly selective inhibitor of IKB kinase that binds at an allosteric site of the enzyme and blocks NE-KB-dependent transcription in mice. J. Biol. Chem. (2003) 278:1450–1406.
- COGHLAN M, TAYLOR J, YEADON M, KILTY IC: Potential anti-inflammatory treatment for asthma and COPD via inhibition of IKK signalasome activity with a small molecule inhibitor, demonstration of whole cell mode of action. Inflam. Res. (2003) 52\(Supp1.2):2–5.
- BUDUNOVA IV, YEMELYANOV A, GASPARIAN A et al.: Effect of IKK-0 specific inhibitor PS1145 on NE-KB activity and apoptosis in prostate carcinoma cell lines. Proc. Am. Assoc. Cancer Res. (2004) 45: abstract 4572.
- MURATA T, SHIMADA M, SAKAKIBARA S et al.: Discovery of novel and selective IKK-0 serine-threonine protein kinase inhibitors. Part 1. Bioorg. Med. Chem. Lett. (2003) 13(5):913–918.
- MURATA T, SHIMADA M, KADONO H et al.: Synthesis and structure—activity relationships of novel IKK-0 inhibitors. Part 2: Improvement of in vitro activity. Bioorg Med. Chem. Lett. (2004) 14(15):4013–4017.
- MURATA T, SHIMADA M, SAKAKIBARA S et al: Synthesis and structure-activity relationships of novel IKK-0 inhibitors. Part 3: Orally active anti-inflammatory agents. Bioorg Med. Chem. Lett. (2004) 14(15):4019–4022.
- BAXTER A. BROUGH S, COOPER A et al.: Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. Bioorg Med. Chem. Lett. (2004) 14(11):2817–2822.
- •The identification and modification of the leads that led to the compounds claimed in these applications.
- KISHORE N, SOMMERS C, MATHIALAGAN S et al.: A selective IKK-2 inhibitor blocks NE-KB-dependent gene expression in interleukin-1 0-stimulated synovial fibroblasts. J. Biol. Chem. (2003) 278(35):32861–32871.
- PODOLIN PL, CALLAHAN JF, BOLOGNESE BJ et al.: Attenuation of murine collagen-induced arthritis by a novel, potent and selective small molecule inhibitor of IKB kinase 2, TPCA-1, occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J. Pharmacol. Exp. Ther. (2004).